Evidence map›Paper›PMID 40162104›Full record

ArticleWorld journal of oncology2025

Comprehensive Investigation of a Tyrosine Kinase Inhibitor-Resistant Gene

Qing Ling Huang, Guan Lan Zhang, Qin Yan Su, Bang Teng Chi, Qian Lin, Shi De Li, Han He, Yu Lu Tang, Yi Wu Dang, Gang Chen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qing Ling HuangDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Guan Lan ZhangDepartment of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Qin Yan SuDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Bang Teng ChiDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Qian LinDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Shi De LiDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Han HeDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Yu Lu TangDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Yi Wu DangDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Gang ChenDepartment of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Rong Quan HeDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tyrosine kinase inhibitors (TKIs) are first-line therapies for hepatocellular carcinoma (HCC), but the drug resistance restricts the long-term clinical outcomes. This study aimed to investigate the expression patterns and possible clinical significance of a TKI-resistant gene Methods: Clustered regularly interspaced short palindromic repeats (CRISPR) screening was conducted to obtain TKI-resistant genes. Pan-cancer analysis was employed to analyze the expression landscape of the critical TKI-resistant gene Results: The abundance of small guide RNA (sgRNA) corresponding to Conclusions:

Indexed as

Hepatocellular carcinomaNucleocytoplasmic transportResistanceTyrosine kinase inhibitorZeste white 10

Identifiers

PMID40162104
PMCPMC11954606

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.